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Abstract: A prevalent cause of sperm dysfunction in male infertility patients is the overproduction
of reactive oxygen species, an attendant increase in lipid peroxidation and the production of cyto-
toxic reactive carbonyl species such as 4-hydroxynonenal. Our previous studies have implicated
arachidonate 15-lipoxygenase (ALOX15) in the production of 4-hydroxynonenal in developing germ
cells. Here, we have aimed to develop a further mechanistic understanding of the lipoxygenase-lipid
peroxidation pathway in human spermatozoa. Through pharmacological inhibition studies, we iden-
tified a protective role for phospholipase enzymes in the liberation of peroxidised polyunsaturated
fatty acids from the human sperm membrane. Our results also revealed that arachidonic acid, linoleic
acid and docosahexanoic acid are key polyunsaturated fatty acid substrates for ALOX15. Upon
examination of ALOX15 in the spermatozoa of infertile patients compared to their normozoospermic
counterparts, we observed significantly elevated levels of ALOX15 protein abundance in the infertile
population and an increase in 4-hydroxynonenal adducts. Collectively, these data confirm the in-
volvement of ALOX15 in the oxidative stress cascade of human spermatozoa and support the notion
that increased ALOX15 abundance in sperm cells may accentuate membrane lipid peroxidation and
cellular dysfunction, ultimately contributing to male infertility.
Keywords: male infertility; lipid peroxidation; spermatozoa; lipoxygenase
1. Introduction
The molecular understanding of male infertility has emerged as a crucial area of
research in view of the growing burden of infertility that afflicts an estimated 15% of
couples globally. While there are many underlying causes of male infertility (discussed
at length in [1]), strong associations have been identified linking male infertility with
increased levels of cellular oxidative stress as measured by reactive oxygen species (ROS)
production and resultant signatures of lipid peroxidation within spermatozoa [2–7]. Ac-
cordingly, in vitro studies have established causality between the induction of cellular
oxidative stress and lipid peroxidation, and a range of adverse functional sequelae, in-
cluding deficits in sperm motility, capacitation, acrosome reaction rates and interactions
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with the zona pellucida [7–9]. Regrettably, however, the knowledge that oxidative stress
and ROS overproduction is intimately tied to sperm dysfunction has done little to provide
improved treatment outcomes to male infertility patients. Indeed, despite the comple-
tion of numerous clinical trials designed to assess the therapeutic utility of antioxidants,
these interventions have thus far failed to deliver on their expectations [10–12]. Whilst
the reasons for these disappointing outcomes are undoubtedly complex, factors such as a
failure to target appropriate patient cohorts, the use of antioxidant formulations that are
not tailored toward the specific stress experienced in the male germline, and inconsisten-
cies in measured outcomes all contribute [13]. Irrespective, the limitations of our current
armoury of antioxidant strategies suggest that more targeted approaches, which exploit
our mechanistic knowledge of male germ cell biology, are urgently needed.
Although lipid peroxidation levels are commonly reported as elevated in dysfunc-
tional spermatozoa following an in vitro induction of oxidative stress [6] or in infertile
patients [14,15], the key mechanisms responsible for driving the lipid peroxidation cascade
downstream of ROS production, remain poorly characterised in human spermatozoa. The
literature pertaining to the lipid peroxidation pathway in the male germ line typically
draw on analogies with somatic cell behaviour, thus leaving many of the fundamental
aspects of this pathway uncharacterised in mature human spermatozoa. This remains
an important avenue for research since the structure and function of the male gamete
fundamentally differs from that of their somatic cell counterparts. Such differences extend
to the unique highly specialised architecture of the spermatozoon in which the cytoplasmic
content, and hence antioxidant capacity, is severely limited combined with the fact that
these cells are transcriptionally and translationally silent and thus incapable of repairing
cellular damage should it arise [16,17]. Accordingly, a more thorough examination of the
molecular mechanisms that underpin the initiation and propagation of lipid peroxidation
within human sperm cells is warranted.
In seeking to address this unmet need, our previous research has focused on the char-
acterisation of the lipoxygenase enzyme, arachidonate 15-lipoxygenase (ALOX15), that is
responsible for catalysing lipid peroxidation via the oxygenation of polyunsaturated fatty
acid (PUFA) substrates [18–20]. Ultimately, ALOX15 facilitates the production of cytotoxic
lipid aldehydes, causing cellular damage that can perpetuate further oxidative insults into
widespread collateral damage throughout the germ cell [13]. In our studies, we have con-
firmed that ALOX15 holds a central role in the lipid peroxidation cascade within mature hu-
man spermatozoa. Indeed, selective ALOX15 inhibition via PD146176 treatment, attenuates
both cellular oxidative stress and lipid peroxidation and maintains sperm functionality [8].
In view of these promising data, this study was designed to generate additional mechanistic
insights into the regulation of lipoxygenase driven lipid peroxidation cascades in human sper-
matozoa and examine the relative abundance of ALOX15 in the spermatozoa of infertile men.
Specifically, we sought to examine the profile of PUFA substrates metabolised by ALOX15, as
well as the involvement of phospholipase enzymes in the upstream liberation of these PUFAs
from within the damaged sperm plasma membrane. With the goal of formulating effective
interventions to prevent the demise of sperm cells in the face of an oxidative insult, we also
evaluated whether ALOX15 works in tandem with additional members of the lipoxygenase
family in mediating human sperm lipid peroxidation. Overall, the insights from this study of
the lipoxygenase-lipid peroxidation pathway operating in human sperm represent important
advances toward the long-term development of tailored therapeutic strategies to reduce the
burden of male infertility associated with oxidative stress.
2. Materials and Methods
2.1. Ethics
All reported studies involving human semen samples were performed in accordance
with the University of Newcastle Human Ethics Committee guidelines (Approval No. H-
2013-0319). Volunteers consisted of a panel of healthy donors with normozoospermic semen
parameters as determined by routine andrological assessment in accordance with WHO
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criteria. Patient recruitment and consent was in accordance with the Human Fertilisation
and Embryology Authority (HFEA) Code of Practice (version 8) and under local ethical
approval (13/ES/0091) from East of Scotland Research Ethics Service (EoSRES) REC1.
All donors and patients provided informed written consent for the use of their samples.
2.2. Reagents
Unless specified below, all chemical reagents were of research grade and were obtained
from Merck (Kenilworth, NJ, USA). Those chemicals sourced from Thermo Fisher Scientific
(Waltham, MA, USA) included BODIPY 581/591 C11 and the LIVE/DEAD viability reagent.
The lipoxygenase inhibitors, PD146176, BW-B-70C and 2-TEDC were purchased from Tocris
Bioscience (Avonmouth, Bristol, UK). ML355 and docosapentanoic acid were supplied
by Cayman Chemical (Ann Arbor, MI, USA). Anti-ALOX15 antibodies were purchased
from Abcam (Cambridge, MA, USA), while GE Healthcare (Chicago, IL, USA) supplied
nitrocellulose membranes and Percoll. Tris-HCl was obtained from ICN Biochemicals
(Castle Hill, NSW, Australia) and Hams-F10 was bought from MP Biomedicals (Irvine, CA,
USA). The catalogue numbers of antibodies and details for the working solutions of each
inhibitor and probe are provided in Supplementary Table S1.
2.3. Preparation of Human Spermatozoa
Human sperm samples were prepared following a 30 min liquefaction period. To sep-
arate high- and low-quality sperm populations, raw semen samples were individually
layered onto a 40%/80% discontinuous Percoll gradient and centrifuged at 500× g for
30 min as previously described [21]. The pellet formed at the bottom of the tube comprises
the sub-population of high-quality spermatozoa within each sample, with the less dense
cells partitioning at the interface of the 40% and 80% fractions representing lower-quality
cells as defined by poorer semen parameters and reduced functional competence [22,23].
Following isolation of this sperm population, the cells were resuspended in 5 mL of non-
capacitating Biggers Whitten and Whittingham (NC BWW) media [24] lacking bicarbonate
and centrifuged for a further 15 min (500× g). Sperm were then resuspended in NC BWW
medium at a concentration of 10 × 106 cells/mL in preparation for experimental analyses.
Commercially available media were used to prepare patient samples at Ninewells Assisted
Conception Unit, Dundee. Spermatozoa were separated from semen by density gradi-
ent centrifugation (40%/80%) using PureCeption diluted with HEPES-buffered human
tubal fluid (HTF) (Cooper Surgical; Måløv, Denmark). After centrifugation, the pellet was
washed by centrifugation (500× g; 10 min) in 4 mL Quinn’s Advantage Medium with
HEPES. If the samples were assigned for IVF, the supernatant was discarded following cen-
trifugation and the pellet resuspended in Quinn’s Advantage Fertilization medium. If the
sample was allocated for ICSI, the cells were washed and prepared in Quinn’s Advantage
Medium with HEPES and HAS.
2.4. Induction of Lipid Peroxidation and Inhibitor Treatment
In the majority of the reported studies, the induction of lipid peroxidation was
achieved by treating spermatozoa with arachidonic acid (AA). Given this, a dose–response
pilot study was performed (5–50 µM) to establish an effective AA concentration with which
to upregulate lipid peroxidation without compromising sperm viability. Following these re-
sults, we elected to use a treatment regimen of 5 µM AA for 30 min at 37 ◦C. Broad spectrum
phospholipase inhibition was achieved using the phospholipase A2 inhibitor, arachidonyl
trifluoromethyl ketone (AACOCF3) [25,26]. Spermatozoa were pre-treated with AACOCF3
(0.05–5 µM) for 30 min at 37 ◦C prior to the induction of lipid peroxidation via challenge
with either H2O2 (1 mM, 1 h, 37 ◦C) or arachidonic acid (AA; 5 µM, 30 min, 37 ◦C). Similarly,
lipoxygenase enzyme activity was inhibited with a range of selective and broad-spectrum
pharmacological reagents. Specifically, ALOX15 was selectively inhibited with PD146176
(6,11-Dihydro[1]benzothiopyrano[4,3-b]indole), ALOX12 with ML355 (N-2-benzothiazolyl-
4-[[(2-hydroxy-3-methoxyphenyl)methyl]amino]-benzenesulfonamide), and ALOX5 with
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BW-B 70C (N-[3-[3-(-fluorophenoxy)phenyl]-1-methyl-2-propenyl]-N-hydroxyurea). Simul-
taneous inhibition of ALOX5, ALOX12 and ALOX15 was accomplished with the broad spec-
trum lipoxygenase inhibitor, 2-TEDC (2-(1-thienyl)ethyl 3,4-dihydroxybenzylidenecyanoac-
etate). Each of these inhibitors was used at concentrations of between 0.05 and 5 µM and
pre-treatment of sperm was completed for 30 min prior to inducing lipid peroxidation with
either arachidonic acid (AA; 5 µM, 30 min, 37 ◦C), linoleic acid (LA; 300 µM, 30 min, 37 ◦C)
or docosahexanoic acid (DHA; 5 µM, 30 min, 37 ◦C) challenge. Importantly, all such PUFAs
are present in human sperm plasma membranes [27] and are documented in a broad range
of cell types to be effective inducers of cellular stress [28–32]. Negative controls for lipid
peroxidation were also completed using the treatments of caprylic acid (5–5000 µM) and
docosapentanoic acid (5–100 µM) (neither of which are recognised lipoxygenase substrates),
without the addition of a lipoxygenase inhibitor. In the final 10 min of each treatment, the
sperm suspension was supplemented with a LIVE/DEAD viability stain (diluted 1:10,000
in NC BWW) in order to facilitate assessment of sperm cell viability.
2.5. Assessment of Lipid Peroxidation
Following isolation of human spermatozoa, cells were incubated with the fluorescent
probe BODIPY 581/591 C11 (5 µM) for 30 min at 37 ◦C as previously described [8]. Based
on shifts in spectral emission maxima, this probe differentiates cells with undamaged
membranes as opposed to those that have experienced lipid peroxidation. Following
incubation with BODIPY 581/591 C11, sperm were washed free of this probe by dilution
into NC BWW and centrifugation in triplicate (500× g, 3 min). Treatments to induce lipid
peroxidation or enzyme inhibition were then completed as previously described. Sperma-
tozoa were then washed in duplicate (500× g, 3 min) and analysed by flow cytometry as
previously described [6]. A minimum of 10,000 cells per treatment were assessed using
a flow cytometer to determine the levels of live BODIPY fluorescent positive cells within
each sample. BODIPY positive cells were determined via spectra emission shifts from
590 to 510 nm. Viability was confirmed using the LIVE/DEAD fluorescent marker where
positive fluorescence indicated non-viable spermatozoa.
2.6. Comparison of ALOX15 Expression in Infertile and Fertile Spermatozoa
Human sperm cells were isolated using Percoll or PureCeption density gradient
centrifugation as described above. Aside from those cells dedicated to the analysis of lipid
peroxidation levels, the remainder of each sample was prepared for protein extraction. For
this purpose, spermatozoa were resuspended in sodium dodecyl sulfate (SDS) extraction
buffer (0.375 M Tris pH 6.8, 2% w/v SDS, 10% w/v sucrose, protease inhibitor cocktail) and
boiled for 5 min at 100 ◦C as previously described [8,33]. Samples were then centrifuged
for 15 min at 17,000× g, 4 ◦C and the solubilised protein recovered in the supernatants
was quantified using a DC protein quantification kit as per the manufacturer’s instructions
(Bio-Rad Laboratories, Hercules, CA, USA). Protein samples were diluted as appropriate
in SDS-PAGE sample buffer (2% v/v mercaptoethanol, 2% w/v SDS, and 10% w/v sucrose
in 0.375 M Tris, pH 6.8 with bromophenol blue) and electrophoresed on precast 4–20%
Tris glycine gel for 1 h at 150 V (Bio-Rad Laboratories, Hercules, CA, USA). Resolved
proteins were then transferred to a nitrocellulose membrane via electroblotting for 1 h at
a constant current of 350 mA. Following protein transfer, the nitrocellulose membranes
were blocked for 1 h with 5% skim milk powder prepared in Tris buffered saline (TBS)
supplemented with 0.1% v/v polyoxyethylenesorbitan monolaurate (Tween-20) and then
incubated overnight (at 4 ◦C) with either an anti-ALOX15 primary antibody or anti-4HNE
primary antibodies (Supplementary Table S1). Following overnight exposure to the primary
antibodies, membranes were washed in triplicate (TBST, 10 min) and then labelled with a
goat-anti-rabbit horseradish peroxidase (HRP)-conjugated secondary antibody (diluted to
0.13 µg/mL in 1% skim milk/TBST). Following secondary antibody incubation, membranes
were again washed in triplicate and developed using an enhanced chemiluminescence
detection kit as per the manufacturer’s recommendations (GE Healthcare).
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2.7. Statistical Analysis
Statistical analyses were completed using JMP statistical software (SAS Institute Inc.,
Cary, NC, USA). The number of replicates (biological and/or technical) is specified in each
figure legend. Importantly, all data sets were initially assessed for normal distribution
using a goodness of fit Shapiro–Wilk test. If normality measures were met, parametric
statistical testing using unpaired Student’s t-tests were completed. In the event that data
were non-normally distributed, non-parametric statistical testing was employed using the
Wilcoxon test. The results for each of these tests are annotated in the appropriate figures
with significance being denoted by the inclusion of asterisks where: * p < 0.05, ** p < 0.01,
and *** p < 0.001.
3. Results
3.1. Arachidonic Acid Treatment Induces Lipid Peroxidation and Cell Death
To pharmacologically manipulate elements of the lipid peroxidation pathway in
human sperm cells, lipid peroxidation was first induced by directly exposing sperm cells to
arachidonic acid. This treatment was chosen on the basis of the specificity of PUFAs to the
lipid peroxidation pathway [34,35] and the documented capacity of AA to induce oxidative
stress [30–32,36]. To establish the efficacy of this approach, a dose–response was performed
using doses of 5–50 µM AA (Figure 1). Significant increases in lipid peroxidation levels
(as measured by BODIPY 581/591 C11 flow cytometry) were observed for all AA treatment
concentrations (Figure 1A; p < 0.01 or p < 0.001), while cell death remained stable until
AA treatments reached a concentration of 30 µM (Figure 1B). Thereafter, cell viability was
compromised in a dose-dependent manner (Figure 1B; p = 0.0314, p = 0.0016, p = 0.0016).
Given these results, we elected to use a treatment regimen of 5 µM AA for 30 min at 37 ◦C
to induce lipid peroxidation.
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Figure 1. Induction of lipid peroxidation with A . High quality human sperm cells wer obtained via Percoll density
centrifugation and then exposed to the BODIPY 581/591 C1 probe (5 µM, 30 min, 37 ◦C) to as es lipid peroxidation (A).
Cells were then treated with A at increasing concentrations (5–50 µM, 30 min, 37 ◦C). To assess viability (B), LIVE/DEAD
was added to each of sample in the final 10 min of AA treatment. Sperm cells were then washed of treatment and analysed
by flow cytometry (counting a minimum of 10,000 cells). Statistical analysis was completed on n = 5 biological replicates,
with all data presented as mean + SEM and with statistically significant changes, compared to the untreated control, being
denoted by * p < 0.05, ** p < 0.01 and *** p < 0.001.
3.2. Phospholipase Inhibition Exacerbates Lipid Peroxidation in Human Spermatozoa
Initial mechanistic studies were designed to assess the involvement of phospholipase
enzymes in the lipid peroxidation pathway of human spermatozoa. In keeping with
the balance of evidence from the somatic cell literature [37–39], we hypothesised that
phospholipase proteins, and in particular those belonging to the phospholipase A2 family,
would be capable of liberating oxidatively damaged PUFAs from sperm membranes.
To validate this hypothesis, human spermatozoa were treated with AACOCF3 (0.05–5 µM),
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a broad-spectrum inhibitor of cytosolic and calcium independent PLA2 [26,27]. Following
pre-treatment with this inhibitor, sperm suspensions were challenged with AA to induce
cellular oxidative stress and lipid peroxidation. The resulting levels of lipid peroxidation
and cell viability were then objectively assessed by flow cytometry. To demonstrate the
validity of the use of AA in these experiments, sperm suspensions were treated in parallel
with H2O2 (as previously described [8]) and the results were compared. As demonstrated
in Figure 2, both H2O2 and AA proved effective treatments for inducing significant levels of
lipid peroxidation compared to the untreated controls (p = 0.0004 and p < 0.0001 respectively,
Figure 2A,C). Co-treatment of sperm with H2O2, and AACOCF3 yielded a significant
increase in lipid peroxidation (p = 0.0009, Figure 2A) and was accompanied by a significant
(p = 0.0014) loss of cell viability (Figure 2B). Similarly, the combined AA and AACOCF3
treatment produced a significant, dose-dependent increase in lipid peroxidation. In this
instance, the highest concentration of AACOCF3 elicited a significant, 3.6-fold increase
in lipid peroxidation above that of the AA treated control (p = 0.0109) (Figure 2C). Such
changes were again aligned with an attenuation of sperm viability (p = 0.0465, Figure 2D).
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3.3. PUFAs (AA, LA, DHA) Serve as Key Substrates for ALOX15 Driven Lipid Peroxidation in
Human Spermatozoa
Having established the principles by which to robustly elicit lipid peroxidation in
human spermatozoa using AA and the involvement of phospholipase enzymes in this
pathway, we next elected to examine the specific involvement of key PUFA substrates in
evoking this response. The rationale for this study rests with independent evidence that
the lipoxygenase-lipid peroxidation pathway is specifically linked to the metabolism of
PUFAs, as opposed to other saturated fatty acids or neutral lipids [40,41]. Furthermore,
the balance of evidence indicates that the catalytic activity of ALOX15 in somatic cells
is allied to a specific subset of PUFAs, namely AA, LA and DHA, which are all present
in human sperm cell membranes [27,42–45]. To assess the involvement of these PUFAs
in the lipoxygenase-lipid peroxidation pathway in human spermatozoa, these cells were
pretreated with the ALOX15 inhibitor PD146176 (0.5 µM) prior to the introduction of
exogenous AA, LA, or DHA (Figure 3). Importantly, each of these three PUFA treatments
proved effective in the induction of cellular lipid peroxidation above that of the basal levels
present in untreated control samples (AA, LA, DHA: p = 0.0028, p < 0.0001, p = 0.0075,
respectively) (Figure 3A,C,E). Furthermore, PD146176-mediated inhibition of ALOX15
significantly attenuated lipid peroxidation levels in all three treatment groups (AA, LA,
DHA: p = 0.0028, p < 0.0001, p = 0.0075, respectively) (Figure 3A,C,E). Notably, amongst these
treatment groups, only LA led to an appreciable reduction in sperm viability (Figure 3D),
a response that was not reversed by prior inhibition of ALOX15 with PD146176 (Figure 3D).
To assess the specificity of the lipoxygenase-lipid peroxidation pathway responses
to PUFAs, equivalent populations of spermatozoa were challenged with dose-dependent
treatments of either caprylic acid (a saturated fatty acid) or docosapentanoic acid (an alter-
native PUFA), neither of which are known substrates for the lipoxygenase enzyme family
(Supplementary Figure S1). Importantly, neither of these treatments resulted in increased
levels of lipid peroxidation.
3.4. ALOX15 Plays a Dominant Role in Lipoxygenase-Mediated Lipid Peroxidation Pathways in
Human Spermatozoa
In view of these collective findings, we sought to assess the therapeutic potential of
modulating lipoxygenase activity as a means by which to protect sperm from lipid peroxi-
dation (Figure 4). Notably, in our previous studies the inhibition of ALOX15 significantly
reduces, but does not completely eliminate, lipid peroxidation levels compared to each
treated control [8]. This led us to hypothesise that alternative lipoxygenase proteins may
participate in the lipid peroxidation pathway in human spermatozoa. To explore the role of
other members of the lipoxygenase family, the contributions of ALOX5 and ALOX12 were
assessed. Of the six lipoxygenase family members, ALOX5 and ALOX12 were selected
based on their tissue expression profile (both are widely expressed, whereas ALOX12B and
ALOXE3 are known to be epithelial-only lipoxygenases), and the availability of specific
inhibitors (there is no available ALOX15B-specific inhibitor). For the purpose of these
studies, AA was used as the substrate to induce the lipid peroxidation pathway, as this
PUFA can be readily processed by most members of the lipoxygenase family [9]. Targeted
inhibition of ALOX12 and ALOX5 was achieved using ML355 (0.34 µM) and BW-B 70C
(0.2 µM), respectively. As shown in Figure 4, both ML355 and BW-B 70C evoked significant,
dose-dependent reductions in lipid peroxidation levels (Figure 4C; p = 0.0029 and p < 0.0001,
Figure 4E p = 0.0014 and p = 0.0014). However, the level of inhibition achieved with ML355
and BW-B 70C was more modest than that of PD146176 (which selectively targets ALOX15)
(Figure 4A,C,E). Moreover, the application of a pan-inhibitor (2-TEDC), which targets
ALOX15, ALOX12 and ALOX5, albeit with varying IC50 values (i.e., ALOX15: 0.5 µM,
ALOX12: 0.013 µM and ALOX5: 0.09 µM; values provided by Tocris Bioscience) provided
additional evidence that ALOX15 may play a dominant role among the lipoxygenase
enzymes examined. Thus, a significant reduction in lipid peroxidation (p = 0.0075) was
only observed when 2-TEDC was used at concentrations greater than or equal to 0.5 µM
(Figure 4G); amounts that far exceed the IC50 value required for selective inhibition of
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either ALOX5 or ALOX12; but equating to the IC50 value expected for ALOX15 inhibition.
Importantly, none of the four inhibitors used in this study had any detrimental impact
on sperm viability, which consistently remained above 80% irrespective of the treatment
group (Figure 4B,D,F,H).
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Figure 4. Lipid peroxidation levels in human spermatozoa following the inhibition of alternative lipoxygenase enzymes.
Initially, cells were incubated with the lipid peroxidation probe BODIPY 581/591 C11 (5 µM). Lipoxygenase inhibition was
then assessed using a range of lipoxygenase inhibitors (A): ALOX15 inhibition-PD146176, (C): ALOX12 inhibition—ML355,
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(E): ALOX5 inhibition—BW-B 70C and (G): multi lipoxygenase inhibitor—2-TEDC using DMSO as the vehicle control.
Following pretreatment of each of these inhibitors for 30 min, lipid peroxidation was induced for an additional 30 min using
5 µM of arachidonic acid (AA). A viability stain of LIVE/DEAD were added to the cells in the final 10 min of this treatment.
Cells were then washed free of treatments in duplicate and then 10,000 live cells were assessed by flow cytometry. Viability
was assessed for each of the treatment groups (B,D,F,H). Statistical analysis was completed using at least n = 4 biological
replicates per treatment group with data presented as mean + SEM. Statistical significance is denoted here by asterisks,
p < 0.01 ** and p < 0.001 ***. For lipid peroxidation levels statistical testing compares samples with treated controls, while
for viability levels show significant changes were determined compared to the untreated control.
3.5. ALOX15 Protein Expression and 4HNE Protein Modifications Are Elevated in Infertile
Patient Sperm Samples
Given that our data indicate that ALOX15 is the primary lipoxygenase family member
involved in the catalysis of peroxidised lipids released from the human sperm membrane,
we elected to examine the abundance of ALOX15 in the spermatozoa of fertile and infertile
men (Figure 5). The cohort of infertile patients examined had experienced a period of
infertility >2 years and possessed sperm parameters (total motility, morphology and cell
number) within a ‘normal’ range according to WHO criteria (Supplementary Table S2). Any
patients with tubal defects or where a female factor was identified were ruled out of this
analysis. Thus, the patients used in this study received a diagnosis of ‘unexplained male
infertility’. Comparison of the sperm lysates from three representative normozoospermic
individuals and three representative individuals with unexplained infertility revealed a
highly significant increase in ALOX15 abundance in the infertile samples (Figure 5A,B,
p < 0.0081). To examine whether an increase in ALOX15 abundance may lead to an increase
in sperm lipid peroxidation in the infertile male population, the profiles of 4HNE-modified
proteins were examined via immunoblotting with anti-4HNE antibodies. This experiment
revealed a significant increase in 4HNE-modified proteins in the infertile sperm lysates,
displaying at least four uniquely modified protein bands compared to the fertile protein
lysates (Figure 5C,D, p = 0.0077). These 4HNE-modified proteins ranged from ~15 to
250 kDa with a small number of constitutively modified proteins also detected in both the
fertile and infertile sperm cells (~45–120 kDa; Figure 5C). This is the first experimental
evidence to link ALOX15 and human sperm lipid peroxidation to a decrease in male fertility.
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Figure 5. Comparison of lipid peroxidation levels and ALOX15 abundance in the spermatozoa
of fertile and infertile males. Immunoblotting was used to quantify ALOX15 abundance (A,B)
and 4HNE protein modifications (C,D) in sperm cell lysates obtained from infertile patients and
fertile donors. Spermatozoa were isolated via Percoll or PureCeption and centrifugation protocols.
Proteins were extracted and resolved by SDS-PAGE in preparation for immunoblotting with either
anti-ALOX15 or anti-4HNE antibodies. Membranes were subsequently stripped and re-probed with
anti-GAPDH antibodies as a loading control. Densitometry of ALOX15 and 4HNE band density was
performed using Image J software. Band density was quantified to compare between infertile and
infertile patient immunoblots (B,D) relative to GAPDH. Statistical analysis was performed on n = 3
biological and n = 3 technical replicates (i.e., one sample from each of three replicate donors and
patients with three technical replicates performed for the immunoblotting procedure). All data are
presented as mean + SEM with statistical significance denoted by ** p < 0.01.
4. Discussion
This study assessed previously unexplored molecular echanisms that underpin
the lipid peroxidation pathway in human spermatozoa, with major findings implicating
ALOX15 in the generation of lipid damage in sperm cells. The involvement of ALOX15
as a catalyst for lipid peroxidation was characteris d via t e validation of its specific
substrates AA, LA and DHA and analysis of the in olvement of phospholipase enzymes.
Furthermore, our comparison of lipid peroxidation levels driven by other members of
the lipoxygenase family, ALOX12 and ALOX5, reveal d that the selective inhibition of
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ALOX15 appeared to be the most effective in reducing levels of lipid peroxidation in
human sperm cells in vitro. Elevated ALOX15 protein abundance in men with fertility
issues compared to normozoospermic donors, occurred concomitant with a significant
increase in 4HNE protein modifications, an important marker of lipid peroxidation and
cellular stress. Ultimately, the data generated in this study have provided an increased
understanding of the lipoxygenase-lipid peroxidation pathway. Indeed, ALOX15 may be a
useful marker for oxidative lipid damage and poor fertility, with the protective effects seen
through pharmacological inhibition of ALOX15 highlighting the potential importance of
targeting this enzyme for the prevention of oxidative stress-induced male infertility.
Phospholipase proteins are involved in the cleavage and liberation of PUFAs from
phospholipids within membranes [46]. These enzymes form part of a broad family of
proteins that are commonly divided among subcategories including secretory (sPLA2),
cytosolic (cPLA2) and calcium independent phospholipases (iPLA2) [39,46]. The role
of phospholipase A2 proteins and their role in membrane PUFA liberation and lipid
peroxidation is not an extensively examined topic in the male germline, however the
studies that have been completed have linked PLA2 proteins to fertility [47]. In particular,
PLA2 levels have been shown to be elevated in the spermatozoa of males suffering from
infertile pathologies such as azoospermia and oligospermia compared to that of their
fertile counterparts [47]. Furthermore, knockout models of PLA2 yielding a significant
depletion of the specific metabolites of ALOX15 (15-HETE, 9-HODE and 13-HODE), thus
providing an important link between PLA2 function and lipoxygenase activity in the male
germline [48].
While there are currently no established mechanistic links between PLA2 activity and
oxidative stress in the male germline, recent studies have confirmed a direct link between
the activity of the antioxidant peroxiredoxin 6 (PRDX-6) and iPLA2 in sperm cells [49,50].
Importantly, in vitro analysis of human sperm confirmed that targeted inhibition of iPLA2
and PRDX-6 resulted in increased levels of lipid peroxidation and decreased sperm function
as observed through compromised acrosome reaction rates [50]. Ultimately, such results
provide support for the increases in lipid peroxidation, and the loss of viability we observed
following the broad-spectrum inhibition PLA2 proteins with AACOCF3 within our study.
Notably, AACOCF3, which is marketed as a cPLA2 inhibitor, has also been documented to
inhibit iPLA2 [25,26]. The increase in lipid peroxidation observed following AA/AACOCF3
treatment is likely to be due to the retention of peroxidised lipids left within the membrane
resulting from compromised PLA2 activity. On the basis of these data, we propose that
the inability to rapidly remove damaged lipids from the proximity of their undamaged
counterparts, propagates membrane instability and may accentuate oxidative stress and
cyclical lipid peroxidation. Moreover, an accumulation of lipid hydroperoxides may take
place under PLA2 inhibitory conditions due to a decrease in detoxification [51]. This is due
to detoxification enzymes present in human sperm cells, such as glutathione peroxidase 4,
acting on lipid hydroperoxides that have already been released from the plasma membrane
by PLA2 enzymes [51].
The literature from somatic cell studies indicates that ALOX15 is able to metabolise
arachidonic acid (AA), linoleic acid (LA) and docosahexanoic acid (DHA) [42–45]. Our
in vitro induction of lipid peroxidation using each of these PUFA substrates was extremely
effective, confirming that each possessed the ability to stimulate lipid peroxidation in
human sperm. Furthermore, the ability of the ALOX15 inhibitor PD146176 to dampen
these responses confirmed that AA, LA and DHA can be utilised as ALOX15 substrates.
Additionally, treatment of sperm cells with lipids that are not metabolised by ALOX15
(i.e., docosapentanoic acid and caprylic acid) failed to elicit any significant increase in lipid
peroxidation (p > 0.05). Overall, these data confirm the involvement of AA, LA and DHA
as specific substrates capable of fueling the lipoxygenase-lipid peroxidation pathway in
human spermatozoa.
Notwithstanding these results, a modest amount of residual lipid peroxidation was
consistently detected following PD146176 treatment. This observation provided an oppor-
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tunity to investigate alternative members of the lipoxygenase family potentially contribut-
ing to the lipid peroxidation pathway in sperm cells. As previously reviewed [9,18,52],
there are six proteins within the lipoxygenase family which include ALOX15, ALOX15B,
ALOX12, ALOX5, ALOX12B and ALOXE3. These proteins are generally divided into two
subgroups based on tissue expression profiles, with ALOX12B and ALOXE3 predominantly
expressed in skin tissue [53,54], whereas all other members of the lipoxygenase family are
documented to be more widely expressed [52]. Excluding the epithelial lipoxygenases,
our analysis focused on the lipoxygenase members ALOX15, ALOX12 and ALOX5 for
which specific inhibitors were commercially available. While the characterisation of these
proteins within the male germline is extremely limited, ALOX5 expression has previously
been linked to fertility [55]. Building on these observations, our analysis focused on the
inhibition of ALOX5, ALOX15 and ALOX12 during the induction of oxidative stress in
male germ cells with AA, confirming that a dose-dependent reduction in lipid peroxidation
could be achieved through the inhibition of each of the three ALOX enzymes individually.
However, the inhibition of ALOX5 and ALOX12, using BW-B 70C and ML355 respec-
tively, only yielded subtle reductions in lipid peroxidation when sperm cells were exposed
to the inhibitors at concentrations close to their predicted IC50 (BW-B 70C: 0.2 µM and
ML355: 0.34 µM; in accordance with the specifications provided by each manufacturer).
By comparison, ALOX15 inhibition, achieved by PD146176 treatment, revealed a dramatic
reduction in lipid peroxidation at its IC50 concentration (0.5 µM; Tocris Bioscience) strongly
supporting the notion that the ALOX15 enzyme may be amongst the dominant enzymes
catalysing the sperm lipid peroxidation pathway. This conclusion was further strength-
ened by the response elicited by the multi lipoxygenase inhibitor 2-TEDC which had IC50
values of 0.09 µM (ALOX5) and 0.013 µM (ALOX12) and 0.5 µM (ALOX15), that required
a supraphysiological concentration of 0.5 µM to induce a significant reduction in lipid
peroxidation compared to the treated control. These data point to a likely prevailing role
for ALOX15 as a master regulator within the lipid peroxidation pathway of human sper-
matozoa and thus highlight the merit of developing clinically safe and effective inhibitors
to prevent ALOX15 action as a strategy to protect human sperm cells from oxidative dam-
age. Notwithstanding these important findings, a caveat to this work is that the role of
ALOX15B remains unknown in human sperm cells. The development of new lipoxygenase
reagents, such as specific activity assays, in the future will enable the further examination
of the lipoxygenase-dependent regulation of sperm membrane lipid peroxidation.
Through the assessment of patient samples, our study has revealed a significant
increase in the abundance of the ALOX15 enzyme in the spermatozoa of a subset of infertile
males with idiopathic infertility. Notably, elevated levels of ALOX15 detected in infertile
sperm lysates were accompanied by a commensurate increase in lipid peroxidation levels
in the sperm of these individuals, as measured by the abundance of 4HNE protein adducts,
a common deleterious outcome downstream of lipid peroxidation. An important caveat
to these findings is the use of IVF medium in the preparation of the clinical samples that
may not be directly comparable in composition to the laboratory medium used to prepare
fertile patient samples. While the use of IVF medium is very unlikely to impact the results
described, independent studies with larger patient cohorts will be important to evaluate
the infertile patient data reported within this manuscript. Notwithstanding this important
caveat, to our knowledge this is the first report of ALOX15 elevation in infertile patients,
which complements independent studies that have recently confirmed increases in both
the ALOX15 substrate AA, and its metabolite, 15-HETE, within the seminal plasma of
infertile individuals [56]. These combined data confirm the link between ALOX15 activity
and oxidative lipid damage in the male germline and provide support for ALOX15 as
both a potential biomarker of male infertility risk and importantly, a powerful target for
preventing oxidative stress-induced male infertility.
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5. Conclusions
Overall, this study has shed new mechanistic light on the lipoxygenase-lipid peroxida-
tion pathway operating within human spermatozoa. Through these data, we propose that
the human sperm lipid peroxidation pathway is initiated both by increases in ROS [8] and
through the ALOX15-dependent oxygenation of PUFAs found in biomembranes (including
AA, LA and DHA) [57]. Moreover, we have demonstrated here that the PLA2 family of en-
zymes is essential in liberating damaged PUFAs from the membrane of oxidatively stressed
human spermatozoa. Without the liberation of these oxidised lipids, effective detoxification
of lipid hydroperoxides by enzymes such as GPX4 is likely to be prevented. The ability of
ALOX15 to additionally oxygenate free fatty acids cleaved from the membrane by PLA2
enzymes may also propagate lipid damage and lead to the production of cytotoxic lipid
aldehydes [41,58]. This study establishes a potential link between ALOX15 and male factor
infertility, demonstrated by the propensity of this enzyme to cause lipid peroxidation and
an overproduction of 4HNE that features in the spermatozoa of infertile patients. These
data provide a platform for the evaluation of ALOX15 abundance and activity in a larger
cohort of infertile male individuals.
Supplementary Materials: The following are available online at https://www.mdpi.com/2076-392
1/10/1/43/s1, Table S1: Summary of the antibodies, fluorophores, pharmacological inhibitors and
incubation media used throughout this study. Supplementary Figure S1. Lipid peroxidation levels of
human spermatozoa following non-specific lipid treatment. Table S2: Sperm parameters recorded for
infertile patients at time of diagnosis.
Author Contributions: J.L.H.W. contributed to experimental planning, conducted the majority of
experimental work and drafted the original manuscript. A.L.A. assisted with experimentation and
manuscript review. S.J.M.d.S. assisted with patient sample acquisition and preparation. R.J.A.,
G.N.D.I., S.J.M.d.S. and J.M.S. assisted with data interpretation and manuscript editing. B.N. and
E.G.B. contributed with project conceptualisation, experimentation, manuscript editing, project
supervision and funding acquisition. All authors have read and agreed to the published version of
the manuscript.
Funding: This study was funded through a National Health and Medical Research Council of
Australia (NHMRC) Project Grant (APP1163319) awarded to BN, EGB and RJA. EGB and BN are
the recipients of an NHMRC CJ Martin Fellowship (APP1138701) and NHMRC Senior Research
Fellowship (APP1154837), respectively. JLHW is the recipient of an Australian Government Research
Training Program (RTP) PhD Scholarship.
Institutional Review Board Statement: All studies involving human semen samples were performed
in accordance with the University of Newcastle Human Ethics Committee guidelines (Approval
No. H-2013-0319). Patient recruitment and consent was in accordance with the Human Fertilisation
and Embryology Authority (HFEA) Code of Practice (version 8) and under local ethical approval
(13/ES/0091) from East of Scotland Research Ethics Service (EoSRES) REC1.
Informed Consent Statement: Informed consent was obtained from all subjects involved in the study.
Data Availability Statement: The data presented in this manuscript and any accompanying raw
data are available upon request from the corresponding author.
Acknowledgments: The authors would like to thank Jodie Powell and Simone Stanger for the
management of human sperm donors essential for this study, and The University of Newcastle’s
Analytical and Biomolecular Research Facility for providing access to the flow cytometer used
throughout the experiments. The authors acknowledge Chris Barratt and Morven Dean at Ninewells
Hospital, The University of Dundee for their input and assistance with patient samples.
Conflicts of Interest: All authors declare that they have no conflict of interest.
Antioxidants 2021, 10, 43 15 of 17
References
1. Barratt, C.L.R.; Björndahl, L.; De Jonge, C.J.; Lamb, D.L.; Martini, F.O.; McLachlan, R.; Oates, R.D.; Van der Poel, S.; St John, B.;
Sigman, M.; et al. The diagnosis of male infertility: An analysis of the evidence to support the development of global WHO
guidance—challenges and future research opportunities. Hum. Reprod. Update 2017, 23, 660–680. [CrossRef] [PubMed]
2. Oborna, I.; Wojewodka, G.; De Sanctis, J.; Fingerova, H.; Svobodova, M.; Brezinova, J.; Hajduch, M.; Novotny, J.; Radova, L.;
Radzioch, D. Increased lipid peroxidation and abnormal fatty acid profiles in seminal and blood plasma of normozoospermic
males from infertile couples. Hum. Reprod. 2010, 25, 308–316. [CrossRef] [PubMed]
3. Pasqualotto, F.; Sharma, R.; Kobayashi, H.; Nelson, D.; Agarwal, A. Oxidative stress in normospermic men undergoing infertility
evaluation. J. Androl. 2001, 22, 316–322. [PubMed]
4. Aitken, R.J.; Clarkson, J.S.; Fishel, S. Generation of reactive oxygen species, lipid peroxidation, and human sperm function.
Biol. Reprod. 1989, 41, 183–197. [CrossRef]
5. Aitken, R.J.; Gibb, Z.; Baker, M.A.; Drevet, J.; Gharagozloo, P. Causes and consequences of oxidative stress in spermatozoa. Reprod.
Fertil. Dev. 2016, 28, 1–10. [CrossRef]
6. Aitken, R.J.; Wingate, J.K.; De Iuliis, G.N.; McLaughlin, E.A. Analysis of lipid peroxidation in human spermatozoa using BODIPY
C11. MHR Basic Sci. Reprod. Med. 2007, 13, 203–211. [CrossRef]
7. Bromfield, E.G.; Aitken, R.J.; Anderson, A.L.; McLaughlin, E.A.; Nixon, B. The impact of oxidative stress on chaperone-mediated
human sperm–egg interaction. Hum. Reprod. 2015, 30, 2597–2613. [CrossRef]
8. Walters, J.L.; De Iuliis, G.N.; Dun, M.D.; Aitken, R.J.; McLaughlin, E.A.; Nixon, B.; Bromfield, E.G. Pharmacological inhibition of
arachidonate 15-lipoxygenase protects human spermatozoa against oxidative stress. Biol. Reprod. 2018, 98, 784–794. [CrossRef]
9. Walters, J.L.; De Iuliis, G.N.; Nixon, B.; Bromfield, E.G. Oxidative stress in the male germline: A review of novel strategies to
reduce 4-hydroxynonenal production. Antioxidants 2018, 7, 132. [CrossRef]
10. Ahmadi, S.; Bashiri, R.; Ghadiri-Anari, A.; Nadjarzadeh, A. Antioxidant supplements and semen parameters: An evidence based
review. Int. J. Reprod. Biomed. 2016, 14, 729–736. [CrossRef]
11. Ross, C.; Morriss, A.; Khairy, M.; Khalaf, Y.; Braude, P.; Coomarasamy, A.; El-Toukhy, T. A systematic review of the effect of oral
antioxidants on male infertility. Reprod. Biomed. Online 2010, 20, 711–723. [CrossRef] [PubMed]
12. Majzoub, A.; Agarwal, A. Systematic review of antioxidant types and doses in male infertility: Benefits on semen parameters,
advanced sperm function, assisted reproduction and live-birth rate. Arab J. Urol. 2018, 16, 113–124. [CrossRef] [PubMed]
13. Bromfield, E.G.; Mihalas, B.P.; Dun, M.D.; Aitken, R.J.; McLaughlin, E.A.; Walters, J.L.H.; Nixon, B. Inhibition of arachidonate 15-
lipoxygenase prevents 4-hydroxynonenal-induced protein damage in male germ cells. Biol. Reprod. 2017, 96, 598–609. [CrossRef]
[PubMed]
14. Suleiman, S.A.; Ali, M.E.; Zaki, Z.; El-Malik, E.; Nasr, M. Lipid peroxidation and human sperm motility: Protective role of vitamin
E. J. Androl. 1996, 17, 530–537.
15. Colagar, A.H.; Pouramir, M.; Marzony, E.T.; Jorsaraei, S.G.A. Relationship between seminal malondialdehyde levels and sperm
quality in fertile and infertile men. Braz. Arch. Biol. Technol. 2009, 52, 1387–1392. [CrossRef]
16. Hermo, L.; Pelletier, R.M.; Cyr, D.G.; Smith, C.E. Surfing the wave, cycle, life history, and genes/proteins expressed by testicular
germ cells. Part 1: Background to spermatogenesis, spermatogonia, and spermatocytes. Microsc. Res. Tech. 2010, 73, 241–278.
[CrossRef]
17. Hermo, L.; Pelletier, R.M.; Cyr, D.G.; Smith, C.E. Surfing the wave, cycle, life history, and genes/proteins expressed by testicular
germ cells. Part 3: Developmental changes in spermatid flagellum and cytoplasmic droplet and interaction of sperm with the
zona pellucida and egg plasma membrane. Microsc. Res. Tech. 2010, 73, 320–363. [CrossRef]
18. Brash, A.R. Lipoxygenases: Occurrence, functions, catalysis, and acquisition of substrate. J. Biol. Chem. 1999, 274, 23679–23682.
[CrossRef]
19. Ivanov, I.; Heydeck, D.; Hofheinz, K.; Roffeis, J.; O’Donnell, V.B.; Kuhn, H.; Walther, M. Molecular enzymology of lipoxygenases.
Arch. Biochem. Biophys. 2010, 503, 161–174. [CrossRef]
20. Ivanov, I.; Kuhn, H.; Heydeck, D. Structural and functional biology of arachidonic acid 15-lipoxygenase-1 (ALOX15). Gene 2015,
573, 1–32. [CrossRef]
21. Nixon, B.; Mitchell, L.A.; Anderson, A.L.; Mclaughlin, E.A.; O’bryan, M.K.; Aitken, R.J. Proteomic and functional analysis of
human sperm detergent resistant membranes. J. Cell. Physiol. 2011, 226, 2651–2665. [CrossRef] [PubMed]
22. Kaneko, S.; Oshio, S.; Kobanawa, K.; Kobayashi, T.; Mohri, H.; Iizuka, R. Purification of human sperm by a discontinuous percoll
density gradient with an innercolumn. Biol. Reprod. 1986, 35, 1059–1063. [CrossRef]
23. Suzuki, K.; Geshi, M.; Yamauchi, N.; Nagai, T. Functional changes and motility characteristics of Japanese Black bull spermatozoa
separated by percoll. Anim. Reprod. Sci. 2003, 77, 157–172. [CrossRef]
24. Biggers, J.; Whitten, W.; Whittingham, D. The culture of mouse embryos in vitro. In Methods in Mammalian Embryology; Daniel,
J.C., Ed.; W. H. Freeman and Company: San Francisco, CA, USA, 1971; pp. 86–116.
25. Ackermann, E.J.; Conde-Frieboes, K.; Dennis, E.A. Inhibition of macrophage Ca-independent phospholipase A by bromoenol
lactone and trifluoromethyl ketones. J. Biol. Chem. 1995, 270, 445–450. [CrossRef] [PubMed]
26. Ong, W.; Farooqui, T.; Kokotos, G.; Farooqui, A.A. Synthetic and natural inhibitors of phospholipases A2: Their importance for
understanding and treatment of neurological disorders. ACS Chem. Neurosci. 2015, 6, 814–831. [CrossRef] [PubMed]
Antioxidants 2021, 10, 43 16 of 17
27. Lenzi, A.; Picardo, M.; Gandini, L.; Dondero, F. Lipids of the sperm plasma membrane: From polyunsaturated fatty acids
considered as markers of sperm function to possible scavenger therapy. Hum. Reprod. Update 1996, 2, 246–256. [CrossRef]
28. Roig-Pérez, S.; Guardiola, F.; Moretó, M.; Ferrer, R. Lipid peroxidation induced by DHA enrichment modifies paracellular
permeability in Caco-2 cells protective role of taurine. J. Lipid Res. 2004, 45, 1418–1428. [CrossRef]
29. Allard, J.P.; Kurian, R.; Aghdassi, E.; Muggli, R.; Royall, D. Lipid peroxidation during n−3 fatty acid and vitamin E supplementa-
tion in humans. Lipids 1997, 32, 535–541. [CrossRef]
30. Vento, R.; D’Alessandro, N.; Giuliano, M.; Lauricella, M.; Carabillo, M.; Tesoriere, G. Induction of apoptosis by arachidonic acid
in human retinoblastoma Y79 cells: Involvement of oxidative stress. Exp. Eye Res. 2000, 70, 503–517. [CrossRef]
31. Das, U. Essential fatty acids enhance free radical generation and lipid peroxidation toinduce apoptosis of tumor cells. Clin. Lipidol.
2011, 6, 463–489. [CrossRef]
32. Koppers, A.J.; Garg, M.L.; Aitken, R.J. Stimulation of mitochondrial reactive oxygen species production by unesterified, unsatu-
rated fatty acids in defective human spermatozoa. Free Radic. Biol. Med. 2010, 48, 112–119. [CrossRef] [PubMed]
33. Reid, A.T.; Lord, T.; Stanger, S.J.; Roman, S.D.; McCluskey, A.; Robinson, P.J.; Aitken, R.J.; Nixon, B. Dynamin regulates specific
membrane fusion events necessary for acrosomal exocytosis in mouse spermatozoa. J. Biol. Chem. 2012, 287, 37659–37672.
[CrossRef] [PubMed]
34. Gaschler, M.M.; Stockwell, B.R. Lipid peroxidation in cell death. Biochem. Biophys. Res. Commun. 2017, 482, 419–425. [CrossRef]
[PubMed]
35. Kühn, H.; Borchert, A. Regulation of enzymatic lipid peroxidation: The interplay of peroxidizing and peroxide reducing enzymes.
Free Radic. Biol. Med. 2002, 33, 154–172. [CrossRef]
36. Aitken, R.; Smith, T.; Lord, T.; Kuczera, L.; Koppers, A.; Naumovski, N.; Connaughton, H.; Baker, M.; De Iuliis, G. On methods
for the detection of reactive oxygen species generation by human spermatozoa: Analysis of the cellular responses to catechol
oestrogen, lipid aldehyde, menadione and arachidonic acid. Andrology 2013, 1, 192–205. [CrossRef] [PubMed]
37. Adibhatla, R.M.; Hatcher, J.F. Phospholipase A2, reactive oxygen species, and lipid peroxidation in CNS pathologies. BMB Rep.
2008, 41, 560–567. [CrossRef] [PubMed]
38. Sun, G.Y.; Xu, J.; Jensen, M.D.; Yu, S.; Wood, W.G.; González, F.A.; Simonyi, A.; Sun, A.Y.; Weisman, G.A. Phospholipase A2 in
astrocytes. Mol. Neurobiol. 2005, 31, 27–41. [CrossRef]
39. Murakami, M.; Kudo, I. Phospholipase A2. J. Biochem. 2002, 131, 285–292. [CrossRef] [PubMed]
40. Walters, J.L.; Gadella, B.M.; Sutherland, J.M.; Nixon, B.; Bromfield, E.G. Male infertility: Shining a light on lipids and lipid-
modulating enzymes in the male germline. J. Clin. Med. 2020, 9, 327. [CrossRef] [PubMed]
41. Ayala, A.; Muñoz, M.F.; Argüelles, S. Lipid peroxidation: Production, metabolism, and signaling mechanisms of malondialdehyde
and 4-hydroxy-2-nonenal. Oxidative Med. Cell. Longev. 2014, 2014, 360438. [CrossRef] [PubMed]
42. Chang, J.; Jiang, L.; Wang, Y.; Yao, B.; Yang, S.; Zhang, B.; Zhang, M. 12/15 Lipoxygenase regulation of colorectal tumorigenesis is
determined by the relative tumor levels of its metabolite 12-HETE and 13-HODE in animal models. Oncotarget 2015, 6, 2879–2888.
[CrossRef] [PubMed]
43. Dobrian, A.D.; Lieb, D.C.; Cole, B.K.; Taylor-Fishwick, D.A.; Chakrabarti, S.K.; Nadler, J.L. Functional and pathological roles of
the 12-and 15-lipoxygenases. Prog. Lipid Res. 2011, 50, 115–131. [CrossRef] [PubMed]
44. Vangaveti, V.; Baune, B.T.; Kennedy, R.L. Hydroxyoctadecadienoic acids: Novel regulators of macrophage differentiation and
atherogenesis. Adv. Endocrinol. Metab. 2010, 1, 51–60. [CrossRef] [PubMed]
45. Wisastra, R.; Dekker, F.J. Inflammation, cancer and oxidative lipoxygenase activity are intimately linked. Cancers 2014, 6,
1500–1521. [CrossRef] [PubMed]
46. Burke, J.E.; Dennis, E.A. Phospholipase A2 structure/function, mechanism, and signaling. J. Lipid Res. 2009, 50, S237–S242.
[CrossRef] [PubMed]
47. Wang, S.; Huang, Y.; Li, B.; Xia, X.; Wang, Z. Detection and clinical significance of phospholipase A2 in semen of male infertile
patients. Natl. J. Androl. 2003, 9, 90–93.
48. Sato, H.; Taketomi, Y.; Isogai, Y.; Miki, Y.; Yamamoto, K.; Masuda, S.; Hosono, T.; Arata, S.; Ishikawa, Y.; Ishii, T. Group III secreted
phospholipase A2 regulates epididymal sperm maturation and fertility in mice. J. Clin. Investig. 2010, 120, 1400–1414. [CrossRef]
49. Moawad, A.R.; Fernandez, M.C.; Scarlata, E.; Dodia, C.; Feinstein, S.I.; Fisher, A.B.; O’Flaherty, C. Deficiency of peroxiredoxin 6
or inhibition of its phospholipase A2 activity impair the in vitro sperm fertilizing competence in mice. Sci. Rep. 2017, 7, 1–13.
[CrossRef]
50. Lee, D.; Moawad, A.R.; Morielli, T.; Fernandez, M.C.; O’Flaherty, C. Peroxiredoxins prevent oxidative stress during human sperm
capacitation. MHR Basic Sci. Reprod. Med. 2017, 23, 106–115. [CrossRef]
51. Sevenian, A.; Muakkaah-Kelly, S.; Montetruque, S. The influence of phospholipase A2 glutathione peroxidase on the membrane
lipid peroxidase. Arch. Biochem. Biophys. 1983, 223, 441–452. [CrossRef]
52. Kuhn, H.; Banthiya, S.; Van Leyen, K. Mammalian lipoxygenases and their biological relevance. Biochim. Biophys. Acta Mol. Cell
Biol. Lipids 2015, 1851, 308–330. [CrossRef] [PubMed]
53. Yu, Z.; Schneider, C.; Boeglin, W.E.; Brash, A.R. Human and mouse eLOX3 have distinct substrate specificities: Implications for
their linkage with lipoxygenases in skin. Arch. Biochem. Biophys. 2006, 455, 188–196. [CrossRef] [PubMed]
54. Krieg, P.; Fürstenberger, G. The role of lipoxygenases in epidermis. Biochim. Biophys. Acta Mol. Cell Biol. Lipids 2014, 1841, 390–400.
[CrossRef] [PubMed]
Antioxidants 2021, 10, 43 17 of 17
55. García-Herrero, S.; Meseguer, M.; Martínez-Conejero, J.A.; Remohí, J.; Pellicer, A.; Garrido, N. The transcriptome of spermatozoa
used in homologous intrauterine insemination varies considerably between samples that achieve pregnancy and those that do
not. Fertil. Steril. 2010, 94, 1360–1373. [CrossRef]
56. Yu, L.; Yang, X.; Ma, B.; Ying, H.; Shang, X.; He, B.; Zhang, Q. Abnormal arachidonic acid metabolic network may reduce sperm
motility via P38 MAPK. Open Biol. 2019, 9, 180091. [CrossRef]
57. Wenzel, S.E.; Tyurina, Y.Y.; Zhao, J.; Croix, C.M.S.; Dar, H.H.; Mao, G.; Tyurin, V.A.; Anthonymuthu, T.S.; Kapralov, A.A.;
Amoscato, A.A. PEBP1 wardens ferroptosis by enabling lipoxygenase generation of lipid death signals. Cell 2017, 171, 628–
641.e26. [CrossRef]
58. Bromfield, E.G.; Walters, J.L.; Cafe, S.L.; Bernstein, I.R.; Stanger, S.J.; Anderson, A.L.; Aitken, R.J.; McLaughlin, E.A.; Dun, M.D.;
Gadella, B.M. Differential cell death decisions in the testis: Evidence for an exclusive window of ferroptosis in round spermatids.
MHR Basic Sci. Reprod. Med. 2019, 25, 241–256. [CrossRef]
